Topic: Protein Interactions
UC Berkeley researchers have come up with a CRISPR “switch” mechanism that keeps the Cas9 enzyme off until it reaches its target.
Merck KGaA has licensed a cloud-based artificial intelligence proteome screening platform from the Toronto-based Cyclica.
AstraZeneca, Cambridge University and Lumicks formed a discovery hub focused on visualizing the molecules behind disease pathways and treatments.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.